A Phase 2/3 interventional study of Ferric carboxymaltose and Ferrous sulfate tablets in Anemia, Iron-Deficiency, Puerperal Disorders and Depression, Postpartum, sponsored by Norwegian University of Science and Technology. Terminated at 3 sites in Norway. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2012-02-17.
Sponsored by Norwegian University of Science and Technology · Phase 2/3, Interventional, and Treatment
200 patients with post partum anemia will be randomised to receive either intravenous iron (intervention group) or peroral iron (control group).
The hypothesis is that intravenous iron supplementation is superior to standard peroral iron.
The study is a multi center phase 3 trial, comprising 3 medium sized obstetrical units in Norway.
The amount of iron given to the intervention group is calculated according to the modified Ganzoni formula. The control group is given the standard regime of 200 mg ferro sulphate daily. In both groups, treatment start at inclusion, within 48 h of delivery.
The sample size was based on power calculations: About 200 participants are required to detect a difference of 0.5 g/dl between the groups (with 80 % power).
Randomization is performed by use of opaque envelopes. An electronic CRF is applied. Laboratory analysis are provided by a recognized Swedish biochemical laboratory.
Apart from hemoglobin and the common iron parameters, the serum concentration of soluble ferritin receptors will be analyzed, as well as hepcidin levels.
Exclusion Criteria:
Peroral iron given as one tablet of ferrous sulfate 100 mg two times daily
Drug: Ferrous sulfate tablets
Intravenous infusion of Ferric Carboxymaltose (Ferinject), the given dose is adapted according to the individual patient's requirement. No other form of iron supplementation is given.
Drug: Ferric carboxymaltose
Intravenous infusion of Ferric carboxymaltose in a dose calculated to meet the individual patient's requirements following the Ganzoni formula
Also known as: Ferinject
Standard tablets containing 100 mg ferrous sulfate, 1 tablet two times daily
Also known as: Duroferon
Haemoglobin concentration
Time frame: 6 weeks
Ferritin
Time frame: 6 weeks
Fatigue
Fatigue scale
Time frame: 6 weeks
Quality of life
SF-36
Time frame: 6 weeks
Post partum depression
Edinburgh Post Partum Depression Scale
Time frame: 6 weeks
This study is terminated, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Norwegian University of Science and Technology